1646P Efficiency of second-line BRAF/MEK inhibitors in BRAFV600 mutated metastatic melanoma patients after first-line immunotherapy failure: A EUMelaReg real-world study.
Saved in:
| Title: | 1646P Efficiency of second-line BRAF/MEK inhibitors in BRAFV600 mutated metastatic melanoma patients after first-line immunotherapy failure: A EUMelaReg real-world study. |
|---|---|
| Authors: | Ellebaek, E.1 (AUTHOR), Weichenthal, M.2 (AUTHOR), Gavrilova, I.3 (AUTHOR), Asher, N.4 (AUTHOR), Meier, F.5 (AUTHOR), von Wasielewski, I.6 (AUTHOR), Dujović, B.7 (AUTHOR), Šabarić, V.8 (AUTHOR), Duvancic, T.9 (AUTHOR), Soria Rivas, A.10 (AUTHOR), Gutierrez Sanz, L.11 (AUTHOR), Haanen, J.B.A.G.12 (AUTHOR), Svane, I.M.1 (AUTHOR), Mohr, P.13 (AUTHOR), Ascierto, P.A.14 (AUTHOR), Mangana, J.15 (AUTHOR), Rutkowski, P.16 (AUTHOR), Gogas, H.17 (AUTHOR), Bastholt, L.18 (AUTHOR), Schadendorf, D.19 (AUTHOR) |
| Source: | Annals of Oncology. 2025 Supplement 2, Vol. 36, pS976-S977. 2p. |
| Database: | Academic Search Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: asn DbLabel: Academic Search Ultimate An: 189420064 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: 1646P Efficiency of second-line BRAF/MEK inhibitors in BRAFV600 mutated metastatic melanoma patients after first-line immunotherapy failure: A EUMelaReg real-world study. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Ellebaek%2C+E%2E%22">Ellebaek, E.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Weichenthal%2C+M%2E%22">Weichenthal, M.</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Gavrilova%2C+I%2E%22">Gavrilova, I.</searchLink><relatesTo>3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Asher%2C+N%2E%22">Asher, N.</searchLink><relatesTo>4</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Meier%2C+F%2E%22">Meier, F.</searchLink><relatesTo>5</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22von+Wasielewski%2C+I%2E%22">von Wasielewski, I.</searchLink><relatesTo>6</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Dujović%2C+B%2E%22">Dujović, B.</searchLink><relatesTo>7</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Šabarić%2C+V%2E%22">Šabarić, V.</searchLink><relatesTo>8</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Duvancic%2C+T%2E%22">Duvancic, T.</searchLink><relatesTo>9</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Soria+Rivas%2C+A%2E%22">Soria Rivas, A.</searchLink><relatesTo>10</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Gutierrez+Sanz%2C+L%2E%22">Gutierrez Sanz, L.</searchLink><relatesTo>11</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Haanen%2C+J%2EB%2EA%2EG%2E%22">Haanen, J.B.A.G.</searchLink><relatesTo>12</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Svane%2C+I%2EM%2E%22">Svane, I.M.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Mohr%2C+P%2E%22">Mohr, P.</searchLink><relatesTo>13</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Ascierto%2C+P%2EA%2E%22">Ascierto, P.A.</searchLink><relatesTo>14</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Mangana%2C+J%2E%22">Mangana, J.</searchLink><relatesTo>15</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Rutkowski%2C+P%2E%22">Rutkowski, P.</searchLink><relatesTo>16</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Gogas%2C+H%2E%22">Gogas, H.</searchLink><relatesTo>17</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Bastholt%2C+L%2E%22">Bastholt, L.</searchLink><relatesTo>18</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Schadendorf%2C+D%2E%22">Schadendorf, D.</searchLink><relatesTo>19</relatesTo> (AUTHOR) – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Annals+of+Oncology%22">Annals of Oncology</searchLink>. 2025 Supplement 2, Vol. 36, pS976-S977. 2p. |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=189420064 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.annonc.2025.08.2274 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 2 StartPage: S976 Titles: – TitleFull: 1646P Efficiency of second-line BRAF/MEK inhibitors in BRAFV600 mutated metastatic melanoma patients after first-line immunotherapy failure: A EUMelaReg real-world study. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Ellebaek, E. – PersonEntity: Name: NameFull: Weichenthal, M. – PersonEntity: Name: NameFull: Gavrilova, I. – PersonEntity: Name: NameFull: Asher, N. – PersonEntity: Name: NameFull: Meier, F. – PersonEntity: Name: NameFull: von Wasielewski, I. – PersonEntity: Name: NameFull: Dujović, B. – PersonEntity: Name: NameFull: Šabarić, V. – PersonEntity: Name: NameFull: Duvancic, T. – PersonEntity: Name: NameFull: Soria Rivas, A. – PersonEntity: Name: NameFull: Gutierrez Sanz, L. – PersonEntity: Name: NameFull: Haanen, J.B.A.G. – PersonEntity: Name: NameFull: Svane, I.M. – PersonEntity: Name: NameFull: Mohr, P. – PersonEntity: Name: NameFull: Ascierto, P.A. – PersonEntity: Name: NameFull: Mangana, J. – PersonEntity: Name: NameFull: Rutkowski, P. – PersonEntity: Name: NameFull: Gogas, H. – PersonEntity: Name: NameFull: Bastholt, L. – PersonEntity: Name: NameFull: Schadendorf, D. IsPartOfRelationships: – BibEntity: Dates: – D: 02 M: 09 Text: 2025 Supplement 2 Type: published Y: 2025 Identifiers: – Type: issn-print Value: 09237534 Numbering: – Type: volume Value: 36 Titles: – TitleFull: Annals of Oncology Type: main |
| ResultId | 1 |
